SCHEMBL263284

SCHEMBL263284

CC(C)n1cc(N)c(=O)c2cc(F)c(NC3CCCCC3)cc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
FOXO1 Q12778 1/20 0.41
ALOX15 P16050 2/20 0.37
KDM4E B2RXH2 2/20 0.36
MAPT P10636 1/20 0.36
CHEK1 O14757 1/20 0.35
NTRK1 P04629 1/20 0.35
MET P08581 1/20 0.35
PIM1 P11309 1/20 0.35
LTK P29376 1/20 0.35
GRK5 P34947 1/20 0.35
MAP2K2 P36507 1/20 0.35
CDK8 P49336 1/20 0.35
NEK2 P51955 1/20 0.35
LIMK1 P53667 1/20 0.35
TYRO3 Q06418 1/20 0.35
MAP4K2 Q12851 1/20 0.35
DYRK1A Q13627 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL261998 0.88 GAA (0.54) GAAMEN1KMT2AFOXO1ALOX15
SCHEMBL261691 0.86 MEN1 (0.52) GAAMEN1KMT2AFOXO1KDM4E
SCHEMBL9277340 0.84 GAA (0.48) GAAMEN1KMT2AFOXO1KDM4E
SCHEMBL262376 0.82 GAA (0.53) GAAMEN1KMT2AFOXO1ALOX15
SCHEMBL262802 0.80 MEN1 (0.48) GAAMEN1KMT2AFOXO1ALOX15
SCHEMBL262584 0.79 MEN1 (0.48) GAAMEN1KMT2AFOXO1KDM4E
SCHEMBL262585 0.79 MEN1 (0.48) GAAMEN1KMT2AFOXO1KDM4E
SCHEMBL4170455 0.78 MEN1 (0.49) GAAMEN1KMT2AFOXO1PTGS1
SCHEMBL14248546 0.78 MEN1 (0.48) GAAMEN1KMT2AFOXO1PTGS1
SCHEMBL27763824 0.78 KMT2A (0.48) GAAMEN1KMT2AFOXO1PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629126-B2 Quinolone derivative or pharmaceutically acceptable salt thereof ASTELLAS PHARMA INC. (JP) 2014-01-14 US disclosed
US-20120136025-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC. (JP) 2012-05-31 US disclosed
US-8133882-B2 Quinolone derivative or pharmaceutically acceptable salt thereof ASTELLAS PHARMA INC (JP) 2012-03-13 US disclosed
EP-1995240-B1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC (JP) 2012-02-22 EP disclosed
US-20090197834-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-08-06 US disclosed
EP-1995240-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Astellas Pharma Inc. (JP) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136025-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF P2RY10, P2RY12, P2RY11 GAA 4203/4885MEN1 3327/4885KMT2A 2966/4885
US-20090197834-A1 QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF P2RY12, P2RY11, P2RY10 GAA 4528/4885MEN1 2994/4885KMT2A 2967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.